Can-Fite Advances Namodenoson to Phase 2b Immunotherapy Trial after >30% Stable Disease
CANF•Can-Fite will advance its pancreatic cancer drug Namodenoson into a Phase 2b trial combining immunotherapy after Phase 2a data showed >30% stable disease rate, 35% of patients remaining on treatment, and some exceeding 16 months of therapy. The upcoming study, to be detailed at the BIO International Convention, will assess progression-free survival, overall survival, and other efficacy endpoints while Can-Fite negotiates partnerships under confidentiality agreements with multiple oncology firms.
1. Phase 2b Study Advancement
Can-Fite will advance its lead compound, Namodenoson, into a Phase 2b combination study with immunotherapy in advanced pancreatic cancer patients based on encouraging Phase 2a data. This marks the next development step for the A3 adenosine receptor agonist after demonstrating initial clinical activity and safety.
2. Phase 2a Study Outcomes
In the ongoing Phase 2a trial for advanced pancreatic adenocarcinoma, Namodenoson exhibited a favorable safety profile with over 30% of evaluable patients achieving stable disease and 35% remaining on therapy, including some patients receiving treatment beyond 16 months.
3. Upcoming Trial Design and Endpoints
The Phase 2b study will focus on efficacy measures such as progression-free survival, overall survival, and disease stabilization in combination with immunotherapy. Detailed trial design elements will be presented during the BIO International Convention in San Diego.
4. Partnership Discussions
Can-Fite has entered confidentiality agreements with multiple oncology companies to explore potential partnerships for the pancreatic cancer program. Business development meetings are planned at the convention to advance these negotiations.
